Daiichi Sankyo's Ranbaxy purchase takes step forward
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas completed the payment of around ¥170.5 billion ($1.70 billion) in relation to its planned purchase ofRanbaxy Laboratories. The sum was paid following the completion last month of an oversubscribed Rs737 ($15.20) per share open offer for 20% of the Indian firm. Daiichi Sankyo is aiming to acquire at least 50.1% of Ranbaxy through a combination of the offer (which involved around 92.5 million shares), the purchase of some 129.9 million shares from the controlling Singh family, a preferential allotment of 46.3 million shares and a subscription of warrants (23.8 million shares).
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports